Scientific Publications Database
Article Title: Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled TrialsAuthors: Andersen, Kathleen M.; Cheah, Jonathan T. L.; March, Lyn; Bartlett, Susan J.; Beaton, Dorcas; Bingham, Clifton O., III; Brooks, Peter M.; Christensen, Robin; Conaghan, Philip G.; D'Agostino, Maria-Antonietta; de Wit, Maarten; Dueck, Amylou C.; Goodman, Susan M.; Grosskleg, Shawna; Hill, Catherine L.; Howell, Martin; Mackie, Sarah L.; Richards, Bethan; Shea, Beverly; Singh, Jasvinder A.; Strand, Vibeke; Tugwell, Peter; Wells, George A.; Simon, Lee S.
Journal: JOURNAL OF RHEUMATOLOGY Volume 46 Issue 8
Date of Publication:2019
Abstract:
Objective. Outcome Measures in Rheumatology (OMERACT) convened a premeeting in 2018 to bring together patients, regulators, researchers, clinicians, and consumers to build upon previous OMERACT drug safety work, with patients fully engaged throughout all phases.Methods. Day 1 included a brief introduction to the history of OMERACT and methodology, and an overview of current efforts within and outside OMERACT to identify patient-reported medication safety concerns. On Day 2, two working groups presented results; after each, breakout groups were assembled to discuss findings.Results. Five themes pertaining to drug safety measurement emerged.Conclusion. Current approaches have failed to include data from the patient's perspective. A better understanding of how individuals with rheumatic diseases view potential benefits and harms of therapies is essential.